secwatch.observer — SEC 8-K summary
======================================

Issuer:     ProMIS Neurosciences Inc. (PMN)
CIK:        0001374339
Form:       8-K
Filed at:   2025-01-10T23:59:59+00:00
Accession:  0001558370-25-000095
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProMIS initiates Phase 1b PRECISE-AD trial of PMN310 in Alzheimer's disease
---------------------------------------------------------------------------

- Phase 1b PRECISE-AD trial initiated; evaluating PMN310 in 100 patients with early Alzheimer's over 12 months.
- PMN310 selectively targets toxic amyloid-beta oligomers, avoiding plaque to reduce ARIA risk associated with existing therapies.
- Phase 1a data showed favorable safety/tolerability profile and drug concentrations in CSF supporting target engagement.
- Certain interim data from PRECISE-AD expected in first half of 2026.
- Trial will assess safety, tolerability, PK, biomarkers, and clinical efficacy measures.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374339/000155837025000095/0001558370-25-000095-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374339/000155837025000095/pmn-20250110x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-000095

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer